IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 336 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,362,292 | +6.0% | 316,629 | -4.2% | 0.01% | +8.3% |
Q2 2023 | $13,554,096 | +14.0% | 330,346 | -0.7% | 0.01% | +9.1% |
Q1 2023 | $11,889,232 | -5.7% | 332,659 | -0.3% | 0.01% | -15.4% |
Q4 2022 | $12,607,173 | -12.3% | 333,788 | +2.8% | 0.01% | -13.3% |
Q3 2022 | $14,368,000 | +24.8% | 324,842 | +4.4% | 0.02% | +25.0% |
Q2 2022 | $11,514,000 | -10.9% | 311,015 | -10.8% | 0.01% | +33.3% |
Q1 2022 | $12,922,000 | +34.5% | 348,863 | +10.5% | 0.01% | +80.0% |
Q4 2021 | $9,611,000 | -5.1% | 315,820 | +4.6% | 0.01% | 0.0% |
Q3 2021 | $10,129,000 | -6.4% | 302,003 | +11.3% | 0.01% | 0.0% |
Q2 2021 | $10,826,000 | +1.2% | 271,396 | +14.1% | 0.01% | -16.7% |
Q1 2021 | $10,699,000 | +49.9% | 237,959 | +88.5% | 0.01% | +50.0% |
Q4 2020 | $7,136,000 | -96.9% | 126,218 | -97.4% | 0.00% | -97.5% |
Q3 2020 | $233,493,000 | -51.8% | 4,920,843 | -40.1% | 0.16% | -56.4% |
Q2 2020 | $484,575,000 | +17.2% | 8,218,699 | -6.0% | 0.37% | -17.6% |
Q1 2020 | $413,496,000 | -22.1% | 8,745,683 | -0.5% | 0.45% | -12.7% |
Q4 2019 | $531,006,000 | +5.3% | 8,790,025 | +4.5% | 0.51% | -10.5% |
Q3 2019 | $504,160,000 | -7.1% | 8,415,289 | -0.3% | 0.57% | -0.5% |
Q2 2019 | $542,712,000 | -22.7% | 8,444,249 | -2.3% | 0.58% | -25.0% |
Q1 2019 | $701,663,000 | +48.3% | 8,644,351 | -1.2% | 0.77% | +25.1% |
Q4 2018 | $473,026,000 | +2.4% | 8,750,014 | -2.3% | 0.61% | +23.0% |
Q3 2018 | $462,060,000 | +19.5% | 8,958,113 | -3.5% | 0.50% | +19.7% |
Q2 2018 | $386,687,000 | +40.1% | 9,279,730 | +48.2% | 0.42% | +28.7% |
Q1 2018 | $276,057,000 | -17.0% | 6,262,651 | -5.3% | 0.32% | -21.7% |
Q4 2017 | $332,599,000 | -5.9% | 6,612,301 | -5.1% | 0.41% | -7.4% |
Q3 2017 | $353,285,000 | -6.8% | 6,968,149 | -6.4% | 0.45% | -12.4% |
Q2 2017 | $378,900,000 | +20.6% | 7,448,380 | -4.7% | 0.51% | +11.6% |
Q1 2017 | $314,155,000 | -21.9% | 7,814,797 | -7.1% | 0.46% | -31.0% |
Q4 2016 | $402,498,000 | +29.6% | 8,415,156 | -0.7% | 0.66% | +36.2% |
Q3 2016 | $310,536,000 | +53.9% | 8,475,347 | -2.2% | 0.49% | +35.0% |
Q2 2016 | $201,778,000 | -39.9% | 8,663,711 | +4.6% | 0.36% | -39.0% |
Q1 2016 | $335,492,000 | -32.9% | 8,283,738 | +2.5% | 0.59% | -32.2% |
Q4 2015 | $500,302,000 | – | 8,078,518 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |